Harrow, Inc. Announces \$50 Million Add-On Offering of Senior Unsecured Notes to Support Growth

Key Highlights for Investors

• Harrow, Inc. (Nasdaq: HROW) is launching an additional \$50 million offering of its 8.625% senior unsecured notes due 2030.
• This add-on will be issued under the same indenture as the existing \$250 million aggregate principal amount of 2030 Notes issued on September 12, 2025.
• The new notes will form a single series with the existing notes, sharing the same terms except for the issuance date and price.
• Proceeds from the offering are earmarked for general corporate purposes, including initiatives to accelerate growth, new product launches, product development activities, strategic business development, and related investments.
• The offering is being conducted privately to qualified institutional buyers and to non-U.S. persons under Rule 144A and Regulation S of the Securities Act, respectively.
• The notes and related guarantees are not registered under the Securities Act and cannot be offered or sold in the U.S. absent an exemption or in certain other circumstances.

Details of the Offering

Harrow, a leading provider of ophthalmic disease management solutions in North America, announced on March 24, 2026, its intention to raise an additional \$50 million through the issuance of senior unsecured notes. These notes, carrying an interest rate of 8.625% and maturing in 2030, will be guaranteed on a senior unsecured basis by Harrow’s existing and future wholly-owned domestic restricted subsidiaries, as well as any other restricted subsidiaries that guarantee or co-issue any of Harrow’s indebtedness. The guarantee is subject to certain exceptions.

The new \$50 million offering will be consolidated with the \$250 million in principal amount of 2030 Notes previously issued, effectively increasing the total to \$300 million. The only differences between the new notes and the existing notes are the date of issuance and the issue price.

Use of Proceeds

Harrow intends to use the net proceeds from this incremental issuance for general corporate purposes. These may include:

• Accelerating growth initiatives, such as new product launches.
• Funding upcoming product development activities.
• Pursuing future strategic business development opportunities.
• Making related investments that support the company’s growth trajectory.

The company did not specify particular projects or acquisitions but indicated an emphasis on activities that could directly impact future growth and market positioning.

Offering Structure and Regulatory Details

The 2030 Notes and related guarantees have not been registered under the Securities Act of 1933, nor under any state or foreign securities laws. As a result, these securities are being offered only to “qualified institutional buyers” under Rule 144A, or outside the United States to non-U.S. persons under Regulation S.

A confidential offering memorandum dated March 24, 2026, is being provided to eligible investors. The company emphasized that this press release does not constitute an offer to sell or a solicitation to buy the notes, and any such offer or solicitation would only be made through the official offering memorandum.

About Harrow, Inc.

Harrow, Inc. is a prominent player in ophthalmic disease management in North America, offering a comprehensive portfolio of products addressing conditions affecting both the front and back of the eye. These include dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and various ocular surface and retina diseases.

The company is committed to delivering safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Forward-Looking Statements and Shareholder Considerations

This announcement contains forward-looking statements, especially regarding the completion and use of proceeds from the offering. Harrow cautions investors that such statements are subject to risks, including market conditions, negotiation of final transaction documents, and general business or financial conditions. There is no assurance that the offering will be completed as described or at all.

Shareholder Note: The successful completion and deployment of the proceeds from this offering could have a material impact on Harrow’s growth trajectory, operational capabilities, and potentially its share value. Conversely, failure to complete the offering or changes in market conditions could negatively impact the company’s expansion plans and investor sentiment.

Contact Information

For further information, investors can contact:
Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to sell or buy securities. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.

View HARROW, INC. Historical chart here